13.12.2013 • NewschemicalsDede WillamsOSHA

U.S. Safety Agency Cites Williams in June Blast

Chemical producer Williams could be fined as much as a $99,000 by the U.S. Occupational Safety and Hazard Administration (OSHA) in connection with an explosion of a propylene fractionator at its Geismar, Louisiana, site last summer.

The agency said it had found six violations of process safety management in the June blast that killed two people and injured 80. It termed one of the violations "willful," meaning that the company failed to develop clear, written procedures for how to change and put idle pressure vessels into service. Five other violations were rated as "serious."

At the time of the incident, the plant was in a turnaround to add capacity for ethylene and polymer grade propylene. Williams said the upgraded facility will be restarted in April with a capacity of 885,000 t/y of ethylene, up from 612,000 t/y previously.

The company and the U.S. Chemical Safety Board are conducting their own evaluations of the causes of the explosion, parallel to the probe by OSHA. The occupational safety board said Williams "cooperated in the investigation in a "full and transparent manner." 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.